Cerebrospinal fluid τ and β-amyloid(I-42) in dementia disorders

被引：47

作者：

Vanmechelen, E

Vanderstichele, H

Hulstaert, F

Andreasen, N

Minthon, L

Winblad, B

Davidsson, P

Blennow, K

机构：

[1] Innogenet NV, B-9052 Ghent, Belgium

[2] Pitea River Valley Hosp, Dept Rehabil, Pitea, Sweden

[3] Malmo Univ Hosp, Neuropsychiat Clin, Dept Clin Neurosci, Malmo, Sweden

[4] Karolinska Inst, Huddinge Univ Hosp, Geriatr Med Sect, Dept Clin Neurosci & Family Med, S-10521 Stockholm, Sweden

[5] Univ Gothenburg, Unit Neurochem, Dept Clin Neurosci, S-41320 Gothenburg, Sweden

来源：

MECHANISMS OF AGEING AND DEVELOPMENT | 2001年 / 122卷 / 16期

关键词：

cerebrospinal fluid; iota; beta-amyloid; Alzheimer's disease; dementia; diagnosis;

D O I：

10.1016/S0047-6374(01)00304-9

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The reliability of cerebrospinal fluid (CSF)-tau and CSF-beta -amyloid assays for diagnosis of Alzheimer's disease and other dementing disorders such as frontotemporal dementia (FTD), dementia with Lewy bodies (DLB) and Creutzfeldt-Jakob disease (CJD) is reviewed. CSF assessment of the two proteins is useful in early diagnosis of AD and to differentiate it from FTD and DLB. Extremely high CSF-tau levels can discriminate CJD from AD. (C) 2001 Elsevier Science Ireland Ltd, All rights reserved.

引用

收藏

页码：2005 / 2011

页数：7

相关论文

共 36 条

[1] Amyloid Aβ40 CSF concentrations correlate to frontal lobe atrophy in frontotemporal dementia [J].

Andersen, C ;

Jensen, M ;

Lannfelt, L ;

Lindau, M ;

Wahlund, LO .

NEUROREPORT, 2000, 11 (02) :287-290

[2] Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment [J].

Andreasen, N ;

Minthon, L ;

Vanmechelen, E ;

Vanderstichele, H ;

Davidsson, P ;

Winblad, B ;

Blennow, K .

NEUROSCIENCE LETTERS, 1999, 273 (01) :5-8

[3] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].

Andreasen, N ;

Hesse, C ;

Davidsson, P ;

Minthon, L ;

Wallin, A ;

Winblad, B ;

Vanderstichele, H ;

Vanmechelen, E ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680

[4] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice [J].

Andreasen, N ;

Minthon, L ;

Davidsson, P ;

Vanmechelen, E ;

Vanderstichele, H ;

Winblad, B ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 2001, 58 (03) :373-379

[5] Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology [J].

Arai, H ;

Morikawa, Y ;

Higuchi, M ;

Matsui, T ;

Clark, CM ;

Miura, M ;

Machida, N ;

Lee, VMY ;

Trojanowski, JQ ;

Sasaki, H .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (02) :262-264

[6]

ARAI H, 1997, ALZHEIMERS RES, V3, P211

[7] tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? [J].

Blennow, K ;

Wallin, A ;

Agren, H ;

Spenger, C ;

Siegfried, J ;

Vanmechelen, E .

MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) :231-245

[8] Assessment of CSF levels of tan protein in mildly demented patients with Alzheimer's disease [J].

Galasko, D ;

Clark, C ;

Chang, L ;

Miller, B ;

Green, RC ;

Motter, R ;

Seubert, P .

NEUROLOGY, 1997, 48 (03) :632-635

[9] High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype [J].

Galasko, D ;

Chang, L ;

Motter, R ;

Clark, CM ;

Kaye, J ;

Knopman, D ;

Thomas, R ;

Kholodenko, D ;

Schenk, D ;

Lieberburg, I ;

Miller, B ;

Green, R ;

Basherad, R ;

Kertiles, L ;

Boss, MA ;

Seubert, P .

ARCHIVES OF NEUROLOGY, 1998, 55 (07) :937-945

[10] Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease [J].

Green, AJE ;

Harvey, RJ ;

Thompson, EJ ;

Rossor, MN .

NEUROSCIENCE LETTERS, 1999, 259 (02) :133-135

← 1 2 3 4 →